Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
STAT+
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Business
STAT+

Gilead agrees to buy Kite Pharma, leaping into CAR-T cancer therapy

  • Adam Feuerstein

By Adam Feuerstein Aug. 28, 2017

Reprints
Kite Pharma
The CAR-T production line at Kite's factory in El Segundo, Calif. Kite Pharma

Investors wanted Gilead Sciences to shake things up with a big, transformative acquisition and that’s what the company did Monday, agreeing to buy Kite Pharma and its CAR-T cancer-killing technology for $11.9 billion.

Gilead is paying $180 per share, all in cash, for Kite, or a 29 percent premium over its closing stock price Friday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Texas judge strikes down major Obamacare provision protecting preventive…
Texas judge strikes down major Obamacare provision protecting preventive care
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
3 keys to successful biopharma-academia drug development collaborations
3 keys to successful biopharma-academia drug development collaborations
Genetic differences in breast tumors may contribute to racial…
Genetic differences in breast tumors may contribute to racial disparities
Listen: Biotech’s monkey shortage, the broken generics market, &…
Listen: Biotech’s monkey shortage, the broken generics market, & conference cancel culture
Former J&J exec, an in-demand free agent, takes the…
Former J&J exec, an in-demand free agent, takes the helm at privately held FogPharma

Recommended Stories